

ELECTRONIC SUPPLEMENTARY INFORMATION


[1₄]Heterophane prototypes containing azolium and/or azole anion-binding motifs

Neus Mesquida,* Immaculada Dinarès, Anna Ibáñez and Ermitas Alcalde*


Laboratori de Química Orgànica, Facultat de Farmàcia, Universitat de Barcelona
Avda. Joan XXIII, s/n. 08028-Barcelona (Spain). E-mail:neusmesquida@ub.edu, ealcalde@ub.edu

Table of Contents

• Scheme S1. Synthesis of dialkyne 6	S-2
• Scheme S2. Attempted synthesis of macrocycle 5·X	S-2
• Scheme S3. Synthesis of azide 9 and alkyne 10	S-2
• NMR spectra and ESI(+)-HRMS spectra of macrocycles 3, 4·2Cl and 5·Cl	S-3
• Table S1. Selected ¹ H NMR spectroscopic data for [1 ₄]cyclophanes 1·2A–5·A at 0.003 M in DMSO-d ₆	S-9
• Table S2. Selected ¹ H NMR spectroscopic data of 1·2A–5·A in DMSO-d ₆ , CD ₃ CN or CDCl ₃ at 0.003 M.....	S-10
• Figure S1. ¹ H NMR spectra of heterophane 3 upon addition of increasing amounts of TBA·Cl	S-11
• Figure S2. ¹ H NMR spectra of heterophane 3 in CDCl ₃ upon addition of increasing amounts of TBA·AcO.....	S-12
• Figure S3. ¹ H NMR spectra and Job plot of 2·2PF₆ in CD ₃ CN upon addition of TBA·Cl.....	S-13
• Figure S4. ¹ H NMR spectra and Job plot of 2·2PF₆ in CD ₃ CN upon addition of TBA·AcO.....	S-14
• Figure S5. ¹ H NMR spectra and Job plot of 2·2PF₆ in CD ₃ CN upon addition of TBA·CN.....	S-15
• Figure S6. ¹ H NMR spectra and Job plot of 4·2PF₆ in CD ₃ CN upon addition of TBA·Cl.....	S-16
• Figure S7. ¹ H NMR spectra and Job plot of 4·2PF₆ in CD ₃ CN upon addition of TBA·AcO.....	S-17
• Figure S8. ¹ H NMR spectra and Job plot of 4·2PF₆ in CD ₃ CN upon addition of TBA·CN.....	S-18
• Figure S9. ¹ H NMR spectra of 2·2PF₆ in DMSO-d ₆ upon addition of TBA·Cl.....	S-19
• Figure S10. ¹ H NMR spectra of 2·2PF₆ in DMSO-d ₆ upon addition of TBA·AcO.....	S-20
• Figure S11. ¹ H NMR spectra of 2·2PF₆ in DMSO-d ₆ upon addition of TBA·H ₂ PO ₄	S-21
• Figure S12. ¹ H NMR spectra of 2·2PF₆ in DMSO-d ₆ upon addition of TBA·CN.....	S-22
• Figure S13. ¹ H NMR spectra of 4·2PF₆ in DMSO-d ₆ upon addition of TBA·Cl.....	S-23
• Figure S14. ¹ H NMR spectra of 4·2PF₆ in DMSO-d ₆ upon addition of TBA·AcO.....	S-24
• Figure S15. ¹ H NMR spectra of 4·2PF₆ in DMSO-d ₆ upon addition of TBA·H ₂ PO ₄	S-25
• Figure S16. ¹ H NMR spectra of 4·2PF₆ in DMSO-d ₆ upon addition of TBA·CN.....	S-26
• Figure S17. ¹ H NMR spectra of 5·PF₆ in CD ₃ CN upon addition of TBA·Cl.....	S-27
• Figure S18. ¹ H NMR spectra of 5·PF₆ in CD ₃ CN upon addition of TBA·AcO.....	S-28
• Figure S19. ¹ H NMR spectra of 5·PF₆ in CD ₃ CN upon addition of TBA·TBA·H ₂ PO ₄	S-29
• Figure S20. ¹ H NMR spectra of 5·PF₆ in CD ₃ CN upon addition of TBA·CN.....	S-30
• Figure S21. ¹ H NMR spectra of 5·PF₆ in DMSO-d ₆ upon addition of TBA·AcO.....	S-31
• Figure S22. ¹ H NMR spectra of 5·PF₆ in DMSO-d ₆ upon addition of TBA·TBA·H ₂ PO ₄	S-32
• Figure S23. ¹ H NMR titration curves of the receptor 2·2PF₆ in CD ₃ CN.....	S-33
• Figure S24. ¹ H NMR titration curves of the receptor 2·2PF₆ in DMSO-d ₆	S-33
• Figure S25. ¹ H NMR titration curves of the receptor 4·2PF₆ in CD ₃ CN.....	S-34
• Figure S26. ¹ H NMR titration curves of the receptor 4·2PF₆ in DMSO-d ₆	S-34
• Figure S27. ¹ H NMR titration curves of the receptor 5·PF₆ in CD ₃ CN.....	S-35
• Figure S28. ¹ H NMR titration curves of the receptor 5·PF₆ in DMSO-d ₆	S-35
• Table S3. Association constants K_a and free energies $-\Delta G^\circ$ for compounds 2·2PF₆ , 4·2PF₆ or 5·PF₆ and TBA·A..S-36	
• Table S4. Average association constants K_a and free energies $-\Delta G^\circ$ for compounds 2·2PF₆ , 4·2PF₆ or 5·PF₆S-37	




Scheme S1 Synthesis of dialkyne **6**: (i) *i*-PrMgCl, THF, 0 °C to rt, 1 h; (ii) CuBr, dibromide **8**, THF, reflux, 5 h; (iii) TBAF·H₂O, AcOH, THF, rt, 18 h.



Scheme S2 Attempted synthesis of macrocycle **5·X**.

(Ref. 1 Alcalde, E.; Ayala, C.; Dinarès, I.; Mesquida, N. *J. Org. Chem.*, **2001**, *66*, 2291–2295)




Scheme S3 Synthesis of azide **9** and alkyne **10**: (i) DIPEA, TBDMSCl, CH₂Cl₂, 0 °C to rt, 18 h; (ii) NaN₃, DMF, 60 °C; (vii) *i*-PrMgCl, THF, 0 °C to rt, 1 h; (iii) CuBr, bromide **16**, THF, reflux, 5 h; (iv) TBAF·H₂O, AcOH, THF, rt, 18 h. TBDMS: (*tert*-butyl)dimethylsilyl group.


NMR SPECTRA AND ESI(+)-HRMS SPECTRA OF MACROCYCLES 3, 4·2Cl AND 5·Cl

• [14]Triazolophane 3


^1H NMR (400 MHz, CDCl_3)





1D-NOESY experiment (CDCl_3)




1D-NOESY experiment (DMSO-d₆)




13C NMR (100.6 MHz, CDCl₃)




• [14]Triazoliophane 4·2Cl




1D-NOESY experiment (DMSO-d₆)




13C NMR (100.6 MHz, CDCl₃, 51.43 mM)






• Hybrid [1₄]heterophane 5·Cl



ROESY experiment (CDCl₃)








Table S1. Selected ^1H NMR (300 MHz, DMSO-d₆) spectroscopic data for [1₄]cyclophanes **1·2A–5·A** at 0.003 M.




Compd.	H(a)	H(b)	H(c)	H(d)	CH ₂ (e)	CH ₂ (f)	CH ₂ (g)	CH ₂ (h)	CH ₂ (i)
1·2Cl	9.03	—	—	—	5.56	—	—	—	—
1·2AcO	8.89	—	—	—	5.42	—	—	—	—
1·2PF₆	9.00	—	—	—	5.52	—	—	—	—
2·2Br	9.37	6.70	—	—	—	5.43	—	—	—
2·2Cl	9.48	6.81	—	—	—	5.42	—	—	—
2·2AcO	10.37	7.31	—	—	—	5.39	—	—	—
2·2H₂PO₄	10.85	7.88	—	—	—	5.39	—	—	—
2·2PF₆	9.28	6.62	—	—	—	5.42	—	—	—
3^{a,b}	—	6.26	7.76	6.23	—	—	5.53	3.93	—
3^{a,b,c}	—	6.41	6.98	6.45	—	—	5.46	4.04	—
4·2Cl^b	—	7.14	8.71	6.70	—	—	5.84	4.25	—
4·2PF₆	—	7.08	8.60	6.66	—	—	5.84	4.25	—
5·Cl	9.35	6.35	7.84	6.33	—	5.39	5.60	4.01	5.37
5·PF₆	9.32	6.31	7.83	6.33	—	5.38	5.60	4.01	5.37
5·PF₆^c	8.81	6.49	7.72	6.56	—	5.29	5.53	4.09	5.26

^a At 0.005 mM. ^b Unambiguous assignments were made by 1D-NOESY (400 MHz).

^c In CDCl₃. ^d Unambiguous assignments were made by ROESY (500 MHz).

Table S2. Selected ^1H NMR (300 MHz) chemical shift values of compounds **1·2A–5·A** in DMSO-d_6 , CD_3CN or CDCl_3 at 0.003 M.




Compd	Anion	DMSO-d ₆				CD ₃ CN				CDCl ₃			
		H(a)	H(b)	H(c)	H(d)	H(a)	H(b)	H(c)	H(d)	H(a)	H(b)	H(c)	H(d)
1·2A^{a,b}	Cl ⁻	9.03	—	—	—								
	PF ₆ ^{-e}	9.00	—	—	—								
	Δδ ^c	0.03											
	AcO ⁻	8.89	—	—	—								
	Δδ ^d	-0.11											
2·2A^b	Cl ⁻	9.48	6.81	—	—	11.00	8.46	—	—				
	PF ₆ ^{-e}	9.28	6.62	—	—	8.35	6.51	—	—				
	Δδ ^c	0.20	0.19			2.65	1.95						
	AcO ⁻	10.37	7.31	—	—	11.43	8.15	—	—				
	Δδ ^d	1.09	0.69			3.08	1.64						
	H ₂ PO ₄ ^{-a}	10.85	7.88	—	—								
	Δδ ^f	1.57	1.26										
3^{a,e}		—	6.26	7.76	6.23					—	6.41	6.98	6.45
4·2A	Cl ⁻	—	7.14	8.71	6.70	—	7.73	9.23	7.16	—	7.84	10.01	7.26
	PF ₆ ^{-e}	—	7.08	8.60	6.66	—	6.71	7.80	6.45	—	7.03	7.90	6.99
	Δδ ^c	0.06	0.11	0.03		1.02	1.43	0.71		0.81	2.11	0.27	
5·A	Cl ⁻	9.35	6.35	7.84	6.33	9.27	6.78	7.84	6.71	11.67	7.47	8.62	7.39
	PF ₆ ^{-e}	9.32	6.31	7.83	6.33	8.37	6.33	7.41	6.36	8.81	6.49	7.72	6.56
	Δδ ^c	0.03	0.04	0.01	0.00	0.90	0.45	0.43	0.35	2.86	0.98	0.90	0.83

^aNot soluble in CD₃CN at 0.003M. ^bNot soluble in CDCl₃ at 0.003M. ^cΔδ, observed chemical shift difference between Cl⁻ salt and the corresponding PF₆⁻ salt. ^dΔδ, observed chemical shift difference between AcO⁻ salt and the corresponding PF₆⁻ salt. ^eNot soluble in D₂O at 0.003M. ^fΔδ, observed chemical shift difference between H₂PO₄⁻ salt and the corresponding PF₆⁻ salt.

Figure S1. ^1H NMR spectra (low-field region) of heterophane **3** upon addition of increasing amounts of TBA·Cl (300MHz, 298 K) *a*) in CDCl_3 , *b*) in DMSO-d_6 .

a)



b)




Figure S2. ^1H NMR spectra (low-field region) of heterophane **3** in CDCl_3 upon addition of increasing amounts of TBA·AcO (300MHz, 298 K).





Figure S3. **a)** ^1H NMR (300MHz, 298K) spectra (low-field region) of receptor **2·2PF₆** in CD₃CN upon addition of increasing amounts of TBA·Cl (from bottom to top).
b) Job's plot representation from values of H(a) or H(b).

a)



b)





Figure S4. **a)** ^1H NMR (300MHz, 298K) spectra (low-field region) of receptor **2·2PF₆** in CD₃CN upon addition of increasing amounts of TBA·AcO (from bottom to top).
b) Job's plot representation from values of H(a) or H(b).

a)



b)





Figure S5. **a)** ^1H NMR (300MHz, 298K) spectra (low-field region) of receptor **2·2PF₆** in CD₃CN upon addition of increasing amounts of TBA·CN (from bottom to top).
b) Job's plot representation from values of H(a) or H(b).

a)



b)





Figure S6. **a)** ^1H NMR (300MHz, 298K) spectra (low-field region) of receptor **4·2PF₆** in CD₃CN upon addition of increasing amounts of TBA·Cl (from bottom to top).
b) Job's plot representation from values of H(a) or H(b).

a)



b)





Figure S7. a) ^1H NMR (300MHz, 298K) spectra (low-field region) of receptor **4·2PF₆** in CD₃CN upon addition of increasing amounts of TBA·AcO (from bottom to top).
b) Job's plot representation from values of H(a) or H(b).

a)



b)







Figure S8. a) ^1H NMR (300MHz, 298K) spectra (low-field region) of receptor **4·2PF₆** in CD₃CN upon addition of increasing amounts of TBA·CN (from bottom to top).
b) Job's plot representation from values of H(a) or H(b).

a)



b) Isotherm could not be fitted to a 1:2 binding model.




Figure S9. ^1H NMR (300MHz, 298K) spectra (low-field region) of receptor **2·2PF₆** in DMSO-d₆ upon addition of increasing amounts of TBA·Cl (from bottom to top).




Figure S10. ^1H NMR (300MHz, 298K) spectra (low-field region) of receptor **2·2PF₆** in DMSO-d₆ upon addition of increasing amounts of TBA·AcO (from bottom to top).




Figure S11. ^1H NMR (300MHz, 298K) spectra (low-field region) of receptor **2·2PF₆** in DMSO-d₆ upon addition of increasing amounts of TBA·H₂PO₄ (from bottom to top).




Figure S12. ^1H NMR (300MHz, 298K) spectra (low-field region) of receptor **2·2PF₆** in DMSO-d₆ upon addition of increasing amounts of TBA·CN (from bottom to top).




Figure S13. ^1H NMR (300MHz, 298K) spectra (low-field region) of receptor **4·2PF₆** in DMSO-d₆ upon addition of increasing amounts of TBA·Cl (from bottom to top).




Figure S14. ^1H NMR (300MHz, 298K) spectra (low-field region) of receptor **4·2PF₆** in DMSO-d₆ upon addition of increasing amounts of TBA·AcO (from bottom to top).




Figure S15. ^1H NMR (300MHz, 298K) spectra (low-field region) of receptor **4·2PF₆** in DMSO-d₆ upon addition of increasing amounts of TBA·H₂PO₄ (from bottom to top).




Figure S16. ^1H NMR (300MHz, 298K) spectra (low-field region) of receptor **4·2PF₆** in DMSO-d₆ upon addition of increasing amounts of TBA·CN (from bottom to top).




Figure S17. ^1H NMR (300MHz, 298K) spectra (low-field region) of receptor **5·PF₆** in CD₃CN upon addition of increasing amounts of TBA·Cl (from bottom to top).




Figure S18. ^1H NMR (300MHz, 298K) spectra (low-field region) of receptor **5·PF₆** in CD₃CN upon addition of increasing amounts of TBA·AcO (from bottom to top).




Figure S19. ^1H NMR (300MHz, 298K) spectra (low-field region) of receptor **5·PF₆** in CD₃CN upon addition of increasing amounts of TBA·H₂PO₄ (from bottom to top).




Figure S20. ^1H NMR (300MHz, 298K) spectra (low-field region) of receptor **5·PF₆** in CD₃CN upon addition of increasing amounts of TBA·CN (from bottom to top).




Figure S21. ^1H NMR (300MHz, 298K) spectra (low-field region) of receptor **5·PF₆** in DMSO-d₆ upon addition of increasing amounts of TBA·AcO (from bottom to top).




Figure S22. ^1H NMR (300MHz, 298K) spectra (low-field region) of receptor **5·PF₆** in DMSO-d₆ upon addition of increasing amounts of TBA·H₂PO₄ (from bottom to top).




Figure S23. ^1H NMR titration curves of the receptor **2·2PF₆** (initial host concentration ca. 3 mM in CD₃CN, 300 MHz) with corresponding TBA salts represented from values of H(a) or H(b).




Figure S24. ^1H NMR titration curves of the receptor **2·2PF₆** (initial host concentration ca. 3 mM in DMSO-d₆, 300 MHz) with corresponding TBA salts represented from values of H(a) or H(b).




Figure S25. ^1H NMR titration curves of the receptor **4·2PF₆** (initial host concentration ca. 3 mM in CD₃CN, 300 MHz) with corresponding TBA salts represented from values of H(c), H(b) or H(d).




Figure S26. ^1H NMR titration curves of the receptor **4·2PF₆** (initial host concentration ca. 3 mM in DMSO-d₆, 300 MHz) with corresponding TBA salts represented from values of H(c), H(b) or H(d).




Figure S27. ^1H NMR titration curves of the receptor **5** $\cdot\text{PF}_6^-$ (initial host concentration ca. 3 mM in CD_3CN , 300 MHz) with corresponding TBA salts represented from values of H(a), H(b), H(c) or H(d).




Figure S28. ^1H NMR titration curves of the receptor **5** $\cdot\text{PF}_6^-$ (initial host concentration ca. 3 mM in DMSO-d_6 , 300 MHz) with corresponding TBA salts represented from values of H(a), H(b), H(c) or H(d).





Table S3. Association constants for each shifted hydrogen atom K_a (M^{-1}) and free energies $-\Delta G^\circ$ ($kJ \cdot mol^{-1}$) for compounds **2·2PF₆**, **4·2PF₆** or **5·PF₆** and various anions at 298 K in CD₃CN and DMSO-d₆.^a



CD₃CN

Anion	Stoichiometry complex	H(a)	H(b)	H(c)	H(d)
2·2PF₆		K_a $-\Delta G^\circ$	K_a $-\Delta G^\circ$	K_a $-\Delta G^\circ$	K_a $-\Delta G^\circ$
Cl ⁻	1:1	5053±70 21.13	4838±132 21.02	— —	— —
AcO ⁻	1:1	8640±562 22.46	9508±562 22.70	— —	— —
CN ⁻	1:1	1148±113 17.47	1251±113 17.68	— —	— —
4·2PF₆					
Cl ⁻	1:1	— —	2101±114 18.95	1585±84 18.26	2146±70 19.01
AcO ⁻	1:1	— —	5864±209 21.50	4580±176 20.89	3952±131 20.52
CN ⁻	1:1	— —	472±5 ^b 15.26	745±57 16.39	787±80 16.52
5·PF₆					
Cl ⁻	1:1	166±15 12.67	190±11 13.00	195±13 13.06	189±9 12.99
AcO ⁻	1:1	509±30 15.44	477±37 15.28	492±27 15.36	502±33 15.41
H ₂ PO ₄ ⁻	1:1	4780±442 20.99	4531±526 ^c 20.86	3553±412 ^c 20.26	3164±386 ^c 19.97
CN ⁻	1:1	95±11 ^b 11.28	78±11 ^d 10.79	84±12 ^d 10.98	102±16 ^e 11.46

DMSO-d₆

Anion	Stoichiometry complex	H(a)	H(b)	H(c)	H(d)
2·2PF₆		K_a $-\Delta G^\circ$	K_a $-\Delta G^\circ$	K_a $-\Delta G^\circ$	K_a $-\Delta G^\circ$
Cl ⁻	1:1 ^f	87±5 11.06	92±6 11.20	— —	— —
AcO ⁻	1:1 ^f	548±44 15.63	371±16 14.66	— —	— —
CN ⁻	1:1 ^f	63±7 ^b 10.27	108±2 11.60	— —	— —
H ₂ PO ₄ ⁻	1:1 ^f	670±83 ^c 16.12	664±93 ^c 16.10	— —	— —
4·2PF₆					
Cl ⁻	1:1 ^f	— —	67±4 10.41	56±3 9.97	64±4 10.30
AcO ⁻	1:1 ^f	— —	176±12 12.81	191±11 13.01	313±1 14.24
H ₂ PO ₄ ⁻	1:1 ^f	— —	218±4 13.34	245±35 ^d 13.63	282±38 ^g 13.98
5·PF₆					
AcO ⁻	1:1	74±6 10.66	76±11 ^d 10.73	72±8 ^b 10.60	76±8 10.73
H ₂ PO ₄ ⁻	1:1	263±14 13.81	197±10 13.09	193±12 13.04	208±14 13.22

^aError ≤ 10% except where noted. ^bError 11%. ^cError 12%. ^dError 14%. ^eError 16%. ^fStoichiometric binding model in which the error is lower. ^gError 13%.

Table S4. Average association constants K_a (M^{-1}) and free energies $-\Delta G^\circ$ ($kJ \cdot mol^{-1}$) for compounds **2·2PF₆**, **4·2PF₆** or **5·PF₆** and various anions at 298 K in CD₃CN and DMSO-d₆^a

Anion	CD ₃ CN			DMSO-d ₆		
	Stoichiometry	K_a	$-\Delta G^\circ$	Stoichiometry	K_a	$-\Delta G^\circ$
2·2PF₆	complex			complex		
Cl ⁻	1:1	4946	21.08	1:1	90	11.13
AcO ⁻	1:1	9074	22.58	1:1	460	15.15
CN ⁻	1:1	1200	17.57	1:1	86	10.94
H ₂ PO ₄ ⁻	<i>b</i>			1:1	667 ^c	16.11
4·2PF₆						
Cl ⁻	1:1	1944	18.74	1:1	62	10.23
AcO ⁻	1:1	4799	20.97	1:1	227	13.35
CN ⁻	1:1	668	16.06		<i>d</i>	
H ₂ PO ₄ ⁻	<i>b</i>			1:1	248	13.65
5·PF₆						
Cl ⁻	1:1	185	12.93		n.d.	
AcO ⁻	1:1	495	15.37	1:1	75	10.68
CN ⁻	1:1	90 ^e	11.13		n.d.	
H ₂ PO ₄ ⁻	1:1	4007 ^f	20.52	1:1	215	13.31

n.d: not determined. ^aAverage association constants from each shifted hydrogen atom. Average errors $\leq 10\%$ except where noted. ^bPrecipitation occurred during titration. ^cAverage error 12%. ^dIf after addition of a large excess of the anion $\Delta\delta \leq 0.1$ ppm, data were not processed. ^eAverage error 14%. ^fAverage error 11%.